Identification of the Clinical Candidate <b>PF-07284890</b> (<b>ARRY-461</b>), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer-Reference-Cited by-同舟云学术

Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer

Published:2024-07-30 Issue:15 Volume:67 Page:13019-13032
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ren Li¹,Moreno David¹,Baer Brian R.²^ORCID,Barbour Patrick³,Bettendorf Tanna⁴,Bouhana Karyn⁴,Brown Karin²,Brown Suzy A.²,Fell Jay B.⁴^ORCID,Hartley Dylan P.²,Hicken Erik J.²^ORCID,Laird Ellen R.²,Lee Patrice²,McCown Joseph²,Otten Jennifer N.⁵,Prigaro Brett⁶,Wallace Ross⁵,Kahn Dean²^ORCID

Affiliation:

1. Enliven Therapeutics, Boulder, Colorado 80301, United States

2. Pfizer Boulder R&D, Boulder, Colorado 80301, United States

3. Think Biosciences, Boulder, Colorado 80301, United States

4. Cogent Biosciences, Boulder, Colorado 80301, United States

5. Loxo Oncology, Louisville, Colorado 80027, United States

6. Cambrex, Longmont, Colorado 80503, United States

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00998

Reference27 articles.

1. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

2. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

3. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

4. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

5. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy